![Dan Teleman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dan Teleman
Plus aucun poste en cours
Fortune : 113 268 $ au 30/09/2026
Profil
Dan Teleman was the founder of PRF Technologies Ltd., founded in 2007, and served as Chief Executive Officer from 2007 to 2010.
Former jobs include Chief Executive Officer at Atox Bio Ltd. from 2011 to 2022, Chief Executive Officer at Pharma Two B Ltd. from 2023 to 2025, Chief Executive Officer & Director at Nasus Pharma Ltd. from 2025 to 2026, Chairman at Tamarix Pharma Ltd from 2021 to 2023, Head-Marketing & Sales at Amgen, Inc., Senior Business Development Officer at W World Corp., Principal at Israel Defense Forces, and Executive Partner at Israel Biotech Fund from 2022 to 2023.
Education includes graduate studies at Ben-Gurion University of the Negev and an MBA from The Fuqua School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NASUS PHARMA LTD. 0,26% | 17/06/2026 | 30 696 ( 0,26% ) | 113 268 $ | 30/09/2026 |
Anciens postes connus de Dan Teleman
| Sociétés | Poste | Fin |
|---|---|---|
| NASUS PHARMA LTD. | Directeur Général | 22/07/2026 |
Pharma Two B Ltd.
 Pharma Two B Ltd. Pharmaceuticals: MajorHealth Technology Develops combination drugs for neurological disorders | Directeur Général | 01/01/2025 |
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech invests in companies located in Israel. The firm targets companies operating in the fields of biotechnology and pharmaceutical sectors. It provides financing for early stage capital requirements. | Private Equity Investor | 01/05/2023 |
Tamarix Pharma Ltd
 Tamarix Pharma Ltd Pharmaceuticals: MajorHealth Technology Develops a novel small compounds for reducing excessive apoptosis | Président | 01/05/2023 |
Atox Bio Ltd.
 Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Directeur Général | 01/05/2022 |
Formation de Dan Teleman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
14
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
W World Corp.
 W World Corp. Pharmaceuticals: MajorHealth Technology Develops specialty pharmaceutical products | Health Technology |
Ben-Gurion University of the Negev
 Ben-Gurion University of the Negev Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Israel Defense Forces
 Israel Defense Forces SovereignGovernment National security | Government |
PainReform Ltd.
 PainReform Ltd. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceuticals for pain treatment | Health Technology |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Health Technology |
Pharma Two B Ltd.
Pharma Two B Ltd. Pharmaceuticals: MajorHealth Technology Develops combination drugs for neurological disorders | Health Technology |
The Fuqua School of Business
 The Fuqua School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech invests in companies located in Israel. The firm targets companies operating in the fields of biotechnology and pharmaceutical sectors. It provides financing for early stage capital requirements. | Finance |
Nasus Pharma Ltd.
 Nasus Pharma Ltd. Pharmaceuticals: MajorHealth Technology Operates as a drug delivery company that develops powder-based intranasal products | Health Technology |
Tamarix Pharma Ltd
Tamarix Pharma Ltd Pharmaceuticals: MajorHealth Technology Develops a novel small compounds for reducing excessive apoptosis | Health Technology |
